Last updated: 11/07/2018 07:35:29
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects with Moderate to Severe Plaque-Type Psoriasis
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects with Moderate to Severe Plaque-Type Psoriasis
Trial description: This double-blind, placebo-controlled study will be conducted at 5 study centers in the United States. Approximately 30 subjects with moderate to severe plaque-type psoriasis will take part. The study will consist of a screening period of up to 21 days, a 12-week treatment period with 7 on-treatment clinic visits (approximately one every 2 weeks) and a post-dosing follow-up clinic visit approximately 30 days after the last dose of study drug is taken.Subjects will be randomized to receive either 250mg, 500mg or 1000mg of study drug or placebo. Study drug will be taken by mouth on a full stomach, every day for 84 days. Vital signs, clinical laboratory results (hematology, chemistry, and urinalysis), ECGs and physical examinations will be assessed at periodic intervals from Day 1 through Day 84. A skin biopsy will be taken at the beginning and the end of the dosing period to evaluate any effects of the study drug on psoriasis. Investigators will perform other psoriasis evaluations (including the Psoriasis Area and Severity Index [PASI] and the Physician’s Global Assessment [PGA] at 5 different times throughout the study to quantify the effects of SRT2104 on psoriasis activity. Subjects will complete questionnaires throughout the study, to document their sense of well-being and mood at 4 different times during the study.Five blood samples will be obtained at different timepoints during the study, to measure the amount of SRT2104 in the body.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Assessment of clinical activity by Improvement score (using Krueger criteria): Number of participants with good or excellent improvement score based on histological assessments of skin biopsies after 12 weeks of exposure
Timeframe: 12 weeks
Number of participants with any adverse events (AE) and serious adverse events (SAE)
Timeframe: Up to Follow-up (Day 114)
Number of participants with hematology and coagulation abnormalities of potential clinical concern
Timeframe: Up to Follow-up (Day 114)
Number of participants with clinical chemistry abnormalities of potential clinical importance
Timeframe: Up to Follow-up (Day 114)
Number of participants with abnormal electrocardiogram (ECG) values
Timeframe: Up to Follow-up (Day 114)
Number of participants with Vital Signs of Potential Clinical Importance
Timeframe: Up to Follow-up (Day 114)
Secondary outcomes:
Number of participants with clinical activity in Psoriasis Area and Severity Index (PASI) score after 4, 8, and 12 weeks of exposure
Timeframe: Weeks 4, 8 and 12
Summary of Physician’s Global Assessment (PGA) score after 4, 8 and 12 weeks of exposure
Timeframe: Weeks 4, 8 and 12
Area under curve (AUC) of 12 weeks of dosing with 0.25 g, 0.5 g and 1.0 g SRT2104 in the fed state in participants
Timeframe: Pre-dose (30 minutes or less before dosing: 1 sample), 0.5 to 2 hours and 3 to 6 hours post-dose (1 sample), 6 to 22 hours post-dose (2 samples) up to Week 12
Maximum plasma concentration (Cmax) of 12 weeks of dosing with 250 milligrams (mg), 500 mg and 1000 mg SRT2104 in the fed state in participants
Timeframe: One sample: Pre-dose (30 minutes or less before dosing), One sample: 0.5 to 2 hours post-dose and 3 to 6 hours post-dose and 2 samples 6 to 22 hours post dose, at any Visit 4 (Day 28 or Week 4), Visit 6 (Day 56 or Week 8) or Visit 8 (Day 84 or Week 12)
Change from Baseline in Fibroblast growth factor 21 (FGF21) as an indicator of the pharmacodynamic effects of SRT2104
Timeframe: Baseline (Day 1) and Days 28, 56 and 84
Change from Baseline in high-sensitivity C-reactive protein (hsCRP) as an indicator of the pharmacodynamic effects of SRT2104
Timeframe: Baseline (Day 1) and Days 28, 56 and 84
Interventions:
Enrollment:
40
Primary completion date:
2011-09-11
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Krueger JG, Suárez-Fariñas M, Cueto I, Khacherian A, Matheson R, Parish LC, Leonardi C, Shortino D, Gupta A, Haddad J, Vlasuk GP and Jacobson EW. A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis. PLoS ONE. 2015;10(11):e0142081
Medical condition
Psoriasis
Product
GSK2245840
Collaborators
GSK
Study date(s)
June 2010 to November 2011
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18 - 80 years
Accepts healthy volunteers
No
- Able and willing to provide written informed consent to participate in the study
- Be male or female aged 18 to 80 years (inclusive)
- Has received systemic non-biologic psoriasis therapy or PUVA phototherapy within 4 weeks prior to the Screening Visit, or had topical psoriasis treatment or UVB phototherapy within 2 weeks prior to the Screening Visit
- Has received previous treatment with biologic agents within 5 drug half-lives (or within 3 months if half-life is unknown) prior to the first dose of SRT2104
Inclusion and exclusion criteria
Inclusion criteria:
- Able and willing to provide written informed consent to participate in the study
- Be male or female aged 18 to 80 years (inclusive)
- Have a diagnosis of clinically confirmed, stable (without recent documented flare within 30 days prior to the Screening Visit), plaque-type psoriasis for at least 6 months involving ≥10% of body surface area
- Have a baseline PASI of ≥10
- Be a candidate for systemic psoriasis therapy, in the opinion of the investigator
- If a female subject of child-bearing potential, be willing to use reliable contraception for the duration of the study, through the 30 day safety follow up telephone call
- Be willing and able to comply with the protocol for the duration of the study
Exclusion criteria:
- Has received systemic non-biologic psoriasis therapy or PUVA phototherapy within 4 weeks prior to the Screening Visit, or had topical psoriasis treatment or UVB phototherapy within 2 weeks prior to the Screening Visit
- Has received previous treatment with biologic agents within 5 drug half-lives (or within 3 months if half-life is unknown) prior to the first dose of SRT2104
- Has received a live vaccination within 4 weeks prior to the Screening Visit or intends to have a live vaccination during the course of the study
- Use of any other non-psoriatic prescription drug therapy, with the exception of any prescription medication administered at a stable dose for at least 6 weeks prior to the Screening Visit; however, the administration of proton pump inhibitors during the study dosing period is prohibited
- Use of any dietary or herbal supplements, with the exception of those administered at a stable dose for at least 6 weeks prior to the Screening Visit
- Has received any investigational drug or experimental procedure within 30 days prior to the first dose of SRT2104
- Has an active infection (e.g., sepsis, pneumonia, abscess, etc.) or be at high risk of developing an infection, in the opinion of the investigator, prior to the first dose of SRT2104
- Has a history of a positive tuberculosis test or a positive tuberculosis test at the Screening Visit that cannot be attributed to a prior BCG inoculation
- Has a positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of the Screening Visit
- Has a positive test for HIV antibody
- Has an abnormal chest x-ray at the Screening Visit which, in the opinion of the investigator, would preclude entry into the trial
- Has a 12-lead electrocardiogram (ECG) with changes considered to be clinically significant on medical review including prolonged QTc intervals as defined below:
- QTcB ≥450 msec (based on single or average QTc value of triplicate ECGs obtained over a brief period)
- QTcB ≥480 msec in subjects with Bundle Branch Block
- Has renal or liver impairment, defined as:
- Serum creatinine level of ≥ 1.4 mg/dL for females and ≥ 1.5 mg/dL for males
- AST and ALT ≥ 2xULN or
- Alkaline phosphatase and bilirubin > 1.5xULN (an isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%)
- Has active neoplastic disease or history of neoplastic disease within 5 years of study entry (except for basal or squamous cell carcinoma of the skin, or carcinoma in situ which have been definitively treated with standard of care approaches)
- Is pregnant or breast-feeding. Confirmation that a female subject is not pregnant must be established by negative pregnancy tests at Screening and Day 1
- Has a significant history of alcoholism or drug/chemical abuse, or consumes more than 3 standard units/day of alcohol. A standard unit of alcohol is defined as 250 mL of beer, 25 mL of spirit, or 125 mL of wine
- History of sensitivity to any of the study medications, or components thereof, or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation
- Has an acute or chronic illness which, in the opinion of the investigator, could pose a threat or harm to the subject
Trial location(s)
Location
GSK Investigational Site
St. Louis, Missouri, United States, 63117
Status
Study Complete
Location
GSK Investigational Site
Johnston, Rhode Island, United States, 02919
Status
Study Complete
Location
GSK Investigational Site
Portland, Oregon, United States, 97223
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10016
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19103
Status
Study Complete
Showing 1 - 6 of 8 Results
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2011-09-11
Actual study completion date
2011-09-11
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website